两种悉达多复方汤剂联合标准对抗疗法治疗轻中度COVID-19的双盲安慰剂对照试验
该双盲安慰剂对照试验纳入125例轻中度COVID-19患者,随机分为安慰剂组、Nilavembu Kudineer(NVK)组和Kaba Sura Kudineer(KSK)组,每组在标准对抗疗法基础上加用相应汤剂60 ml每日两次,最多10天。结果显示NVK和KSK组在住院时间、病毒载量下降和症状转阴时间上均显著优于安慰剂组,且KSK组主要结局优于NVK组,不良事件少。
要点
- NVK和KSK联合标准治疗可显著缩短轻中度COVID-19患者住院时间。
- NVK和KSK组病毒载量下降及症状转阴时间显著优于安慰剂组。
- KSK组主要结局指标显著优于NVK组,不良事件少。
核心结论
- 与安慰剂(脱咖啡因茶)相比,NVK和KSK组在住院时间、SARS-CoV-2病毒载量下降及症状转阴时间上均呈统计学显著改善。
- KSK组的主要结局指标显著优于NVK组。
研究设计与样本
- 双盲、安慰剂对照比较性临床试验,纳入125例轻中度COVID-19症状患者,研究期4个月(2020年8月至12月)。
- 参与者随机分为3组:I组安慰剂(脱咖啡因茶)、II组NVK、III组KSK,每组接受相应治疗60 ml每日两次(早晚餐后),联合标准对抗疗法,最多10天。
主要发现
- NVK和KSK组住院时间(均值[SD])分别为4.7[1.5]天和4.2[1.5]天,显著短于安慰剂组的8.4[2.0]天(Kruskal-Wallis检验,P=0.0001)。
- NVK和KSK组症状转阴时间均值分别为2.5天和1.7天,显著短于安慰剂组的4.2天(Kruskal-Wallis检验,P=0.0001)。
- 第6天时,NVK和KSK组所有入组参与者(100%)均出院,而安慰剂组仅42.5%(n=17)出院。
- IL-6均值在NVK组为2.6、KSK组为2.2、安慰剂组为4.0,组间差异显著(P=0.02)。
- 共记录2例不良事件:I组1例呕吐,II组1例腹泻,均持续1天。
关键数值与推荐
- 住院时间:I组均值8.4天(SD=2.0),II组4.7天(SD=1.5),III组4.2天(SD=1.5),Kruskal-Wallis检验P=0.0001。
- 症状转阴时间:II组均值2.5天,III组1.7天,I组4.2天,Kruskal-Wallis检验P=0.0001。
- 第6天出院比例:II组和III组均为100%,I组为42.5%(n=17)。
- IL-6均值:NVK=2.6,KSK=2.2,安慰剂=4.0,P=0.02。
临床怎么用
- 对于轻中度COVID-19患者,在标准对抗疗法基础上加用NVK或KSK可能缩短住院时间和症状持续时间。
- KSK在主要结局指标上表现优于NVK,但需结合患者具体情况和当地药物可及性选择。
局限性
- 研究仅纳入125例患者,样本量有限。
- 研究期间为2020年8月至12月,结果可能受病毒株和医疗环境变化影响。
- 随访30天仅通过电话评估不良事件,可能存在报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM: Globally, the ongoing pursuit in exploring an effective drug to combat severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) virus has not met with significant success to date. Indian traditional medicines, especially polyherbal formulations like Nilavembu Kudineer (NVK) and Kaba Sura Kudineer (KSK) of the Siddha system of medicine, have been used as public health interventions for controlling viral epidemics like dengue and Chikungunya. These traditional therapies have been found safe, effective, and widely accepted. The current study evaluates the comparative efficacy of NVK and KSK as opposed to the placebo, in the management of mild to moderate COVID-19 disease. METHODS: The study was a double-blind, placebo-controlled comparative clinical trial, with the primary objective of determining the efficacy of KSK and NVK. Patients (n=125) diagnosed with mild to moderate COVID-19 symptoms were enrolled in the study over a period of 4 months (Aug 2020-Dec 2020). Participants were randomized into 3 arms; placebo-decaffeinated tea in Arm I, NVK in Arm II, and KSK in Arm III. Each arm received 60 ml of the respective treatment twice a day, post morning and evening meals, along with standard allopathy treatment for a maximum of 10 days. The main outcome measures of the study were the reduction in SARS-CoV-2 viral load, hospital stay, and time taken by the patients to become asymptomatic from symptomatic. Efficacy assessments included clinical symptoms (fever, cough, and breathlessness) each day and real-time reverse transcription-polymerase chain reaction (RT-PCR), liver function test (LFT), renal function test (RFT), and electrolytes and electrocardiogram (ECG) at baseline (day 0) and days 3, 6, and 10. Post-treatment, participants were followed up for 30 days via phone for adverse effects if any. Effects of drugs on inflammatory markers (IL6) at the end of treatment were also recorded. Adverse events (AE) were monitored throughout the study. RESULTS: The results revealed that when compared to patients in the placebo arm, those in NVK and KSK arms showed a statistically significant reduction in hospital stay time, reduction in viral load of SARS-CoV-2, and the time taken to become symptomatic from asymptomatic. Out of 125 COVID-19 patients recruited, 120 completed the study; two from the placebo group developed severe symptoms and were shifted to the intensive care unit (ICU) and three patients from Arms II and III withdrew from the study. The mean age of females (n=60) and males (n=60) enrolled was between 40.2 and 44.3 years, respectively. Results were more promising for all the patients in NVK and KSK arms as all enrolled participants (100%) under this group got discharged by day 6 as compared to only 42.5% (n=17) from the placebo group on that day. The hospital stay time for patients in Arm I was significantly longer (mean [SD]=8.4 [2.0] days) as compared to the Arms II and III (mean [SD]=4.7 [1.5] and 4.2 [1.5] days, respectively (Kruskal-Wallis test, P=0.0001). Patients in the three groups took a significantly different number of days to become asymptomatic. While Arm II and III patients took mean of 2.5 and 1.7 days, respectively, Arm I, patients took a mean of 4.2 days (Kruskal-Wallis test, P=0.0001). In all, two adverse events were recorded, one for vomiting and one for diarrhea lasting a day in Arm I and Arm II, respectively. The mean value of interleukin-6 (IL6) was significantly different in comparison to the placebo-decaffeinated tea arm (NVK=2.6 and KSK=2.2, placebo=4.0, P=0.02). The other blood biochemical parameters like C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, and D-dimer that were analyzed at the baseline and at the time of discharge from the hospital, were not significantly different in the three arms. CONCLUSION: NVK and KSK arms showed a statistically significant reduction in hospital stay time, reduction in viral load of SARS-CoV-2, and time taken for patients to become asymptomatic from symptomatic, when compared to the placebo (decaffeinated tea). The primary outcome measures of the KSK arm were significantly better than those in the NVK arm.
引用
- Srivastava A, Rengaraju M, Srivastava S, et al. Efficacy of two siddha polyherbal decoctions, Nilavembu Kudineer and Kaba Sura Kudineer, along with standard allopathy treatment in the management of mild to moderate symptomatic COVID-19 patients-a double-blind, placebo-controlled, clinical trial. Trials. 2021. PMID: 34454572. doi:10.1186/s13063-021-05478-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。